PharmaDrug Inc.
Braxia Scientific will be carrying out a landmark clinical trial investigating multiple-dose psilocybin for treatment-resistant depression.
A psychedelic medicine startup will be developing a transdermal patch for sustained delivery of psilocin.
People will now be able to participate in psychedelic-assisted therapy in a group setting as the Institute for Integrative Therapies expands its services to support the...
Awakn Life Sciences will be carrying out the first-ever study investigating the use of ketamine treatment for gambling addiction, using psychedelic-assisted psychotherapy.
Mydecine Innovations Group has signed a five-year psychedelic research agreement with Johns Hopkins University School of Medicine.
Psycheceutical has been granted exclusive license of two major patents that will psychedelic compounds to be administered without any side effects.
Diamond Therapeutics has received approval from Health Canada to carry out a clinical trial for the treatment of mental health conditions with low-dose psilocybin.
A systematic review of medical research has shown that ketamine and esketamine show no adverse cognitive effects in treatment-resistant depression.
Salvinorin A, derived from the plant Salvia divinorum, is to be researched as a treatment for mental health conditions.